Barclays analyst Carter Gould raised the firm’s price target on Merck to $130 from $128 and keeps an Overweight rating on the shares post the Q1 results. The analyst says Gardasil and Keytruda momentum provide near-term upside.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRK: